Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement or ROS proto-oncogene 1 (ROS1) rearrangement are generally sensitive to tyrosin···【more】
Article source：Captain MedicineRelease date：2024-11-20Recommended：353
Lorlatinib is a highly potent third-generation ALK and ROS1 tyrosine kinase inhibitor with good brain penetration and broad coverage of ALK mutations. In a phase 1 study, it showed···【more】
Article source：Captain MedicineRelease date：2024-11-20Recommended：375
The tropomyosin receptor kinase (TRK) fusion protein produced by the fusion of the neurotrophic tyrosine receptor kinase (NTRK) gene is a major oncogenic driver that is rare in a v···【more】
Article source：Captain MedicineRelease date：2024-11-19Recommended：363
How to buy generic larotrectinib?Vitrakvi, a highly selective oral tropomyosin receptor kinase (TRK) inhibitor, larotrectinib, has demonstrated significant activity in adult and pe···【more】
Article source：Captain MedicineRelease date：2024-11-19Recommended：268
1. Product IngredientsEntrectinib is a small molecule tyrosine kinase inhibitor with the chemical name N-(4-(3-(4-(6-(2-fluoro-4-(trifluoromethyl)phenyl)thiazol-2-yl)thiazol-2-yl)p···【more】
Article source：Captain MedicineRelease date：2024-11-18Recommended：334
1. Product IngredientsThe chemical name of afatinib is N-{4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl}-2-(dimethylamino)acetamide, the molecular for···【more】
Article source：Captain MedicineRelease date：2024-11-18Recommended：302
In a phase 1 study, sotorasib showed anticancer activity in patients with advanced solid tumors with KRAS p.G12C mutations, and particularly promising anticancer activity was obser···【more】
Article source：Captain MedicineRelease date：2024-11-15Recommended：244
According to NCCN guidelines, for patients with KRASG12C-mutated non-small cell lung cancer (NSCLC), two drugs are currently approved for second-line therapy, particularly for pati···【more】
Article source：Captain MedicineRelease date：2024-11-15Recommended：346
Cabobrutinib is a tyrosine kinase inhibitor that primarily targets MET, VEGFR and RET proteins for the treatment of medullary thyroid cancer and advanced renal cellsIs Cabozantinib···【more】
Article source：Captain MedicineRelease date：2024-11-14Recommended：321
Pralsetinib is a selective RET kinase inhibitor indicated for the treatment of RET-fused cancers (NSCLC) and RET-altered thyroid cancers.Where to buy Pralsetinib is reliable?1. Hos···【more】
Article source：Captain MedicineRelease date：2024-11-14Recommended：360
Elacestrant, a non-steroidal small molecule, is an estrogen receptor (ER) antagonist. Erastratran binds to estrogen receptor α (ERα) and acts as a selective estrogen receptor degra···【more】
Article source：Captain MedicineRelease date：2024-11-13Recommended：318
Balversa is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) used to treat cancer. It is the first personalized treatment drug for susceptible FGFR gene mutat···【more】
Article source：Captain MedicineRelease date：2024-11-13Recommended：363
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4452025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6322024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：892026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：4142025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4322025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4172025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4732025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3832025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
